JP7304287B2 - 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 - Google Patents

抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 Download PDF

Info

Publication number
JP7304287B2
JP7304287B2 JP2019534209A JP2019534209A JP7304287B2 JP 7304287 B2 JP7304287 B2 JP 7304287B2 JP 2019534209 A JP2019534209 A JP 2019534209A JP 2019534209 A JP2019534209 A JP 2019534209A JP 7304287 B2 JP7304287 B2 JP 7304287B2
Authority
JP
Japan
Prior art keywords
antibody
csf
cancer
antagonist
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502231A (ja
JP2020502231A5 (enExample
Inventor
ミヒャエル カナリール，
アナ－マリア イェッグ，
フランチェスカ ミキエリン，
カロラ リース，
ドミニク リュッティンガー，
マルティン ヴァイサー，
Original Assignee
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2020502231A publication Critical patent/JP2020502231A/ja
Publication of JP2020502231A5 publication Critical patent/JP2020502231A5/ja
Priority to JP2021169309A priority Critical patent/JP2022025088A/ja
Application granted granted Critical
Publication of JP7304287B2 publication Critical patent/JP7304287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019534209A 2016-12-22 2017-12-20 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療 Active JP7304287B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021169309A JP2022025088A (ja) 2016-12-22 2021-10-15 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16206066 2016-12-22
EP16206066.9 2016-12-22
PCT/EP2017/083696 WO2018115051A1 (en) 2016-12-22 2017-12-20 Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021169309A Division JP2022025088A (ja) 2016-12-22 2021-10-15 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療

Publications (3)

Publication Number Publication Date
JP2020502231A JP2020502231A (ja) 2020-01-23
JP2020502231A5 JP2020502231A5 (enExample) 2021-03-11
JP7304287B2 true JP7304287B2 (ja) 2023-07-06

Family

ID=57588869

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534209A Active JP7304287B2 (ja) 2016-12-22 2017-12-20 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
JP2021169309A Pending JP2022025088A (ja) 2016-12-22 2021-10-15 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021169309A Pending JP2022025088A (ja) 2016-12-22 2021-10-15 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療

Country Status (6)

Country Link
US (1) US11498968B2 (enExample)
EP (1) EP3558360A1 (enExample)
JP (2) JP7304287B2 (enExample)
CN (1) CN110072553B (enExample)
TW (1) TW201828985A (enExample)
WO (1) WO2018115051A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
WO2018115051A1 (en) * 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
AU2019288728A1 (en) * 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
US12454573B2 (en) * 2021-11-02 2025-10-28 Synox Therapeutics UK Limited Dosages of emactuzumab

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011160A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
JP2016531150A (ja) 2013-09-12 2016-10-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体とヒトｐｄ−ｌ１に対する抗体の併用療法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
CA2137793C (en) 1992-06-09 2003-04-22 Jayvardhan Pandit Crystallization of m-csf
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
AU747898B2 (en) 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
CA2304354A1 (en) 1997-10-02 1999-04-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE19935756A1 (de) 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
PT1223980E (pt) 1999-10-28 2003-10-31 Reinhold Hofbauer Utilizacao de inibidores de csf-1
PT1242438E (pt) 1999-12-29 2007-02-28 Immunogen Inc Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DK1572106T3 (da) 2002-11-15 2010-08-23 Novartis Vaccines & Diagnostic Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
PL2489364T3 (pl) 2003-11-06 2015-06-30 Seattle Genetics Inc Związki monometylowaliny zdolne do sprzęgania do przeciwciał
AU2005267062C1 (en) 2004-07-22 2013-01-17 Five Prime Therapeutics, Inc. Compositions and methods of use for MGD-CSF in disease treatment
EP1858928A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
MX351401B (es) 2005-06-08 2017-10-13 Dana Farber Cancer Inst Inc Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
KR20080079301A (ko) 2005-12-09 2008-08-29 시애틀 지네틱스, 인크. Ｃｄ４０ 결합제를 이용하는 방법
AU2007205048B2 (en) 2006-01-05 2013-07-04 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
MX2009006230A (es) 2006-12-12 2009-06-22 Idera Pharmaceuticals Inc Agonistas sinteticos de receptores de tipo toll 9.
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
CN101636412A (zh) 2007-03-30 2010-01-27 霍夫曼-拉罗奇有限公司 标记的和非标记的单克隆抗体的组合物
BRPI0812400A2 (pt) 2007-06-05 2014-10-29 Univ Yale Unidade, hibridoma, composição farmacêutica, método para identificar uma unidade, anticorpo isolado a uma unidade de ligação de antígeno do mesmo, molécula peptídica, e, uso da unidade.
PT2188313T (pt) 2007-08-21 2017-12-12 Amgen Inc Proteínas de ligação ao antigénio c-fms humano
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
EP2262836B1 (en) 2008-03-14 2016-03-09 Transgene SA Antibody against the csf-1 r
WO2009120899A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. G coupled protein receptors associated with myelogenous haematological proliferative disorders and uses thereof
FI4209510T3 (fi) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
WO2010088395A2 (en) 2009-01-30 2010-08-05 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
EP2423228B1 (en) 2009-04-20 2015-12-16 Kyowa Hakko Kirin Co., Ltd. Antibody containing igg2 having amino acid mutation introduced therein
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
SI2510010T1 (sl) 2009-12-10 2016-02-29 F. Hoffmann-La Roche Ag Protitelesa, vezavna na ekstracelično domeno 4 humanega csf1r in njihova uporaba
JP2013521765A (ja) 2010-03-05 2013-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
RU2617966C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
EP2640420B1 (en) 2010-11-19 2018-08-15 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
FR2975600B1 (fr) 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US9243066B2 (en) 2011-07-18 2016-01-26 University Of Melbourne Use of M-CSF antibodies in the treatment of osteoarthritis or pain
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
TWI539961B (zh) 2012-11-09 2016-07-01 轉殖基因公司 單核球或其前驅細胞分化之調節
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EA201790339A1 (ru) 2014-08-12 2017-06-30 Аллигатор Байосайенс Аб Комбинированные препараты с антителами к cd40
WO2016069727A1 (en) * 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN106999583A (zh) * 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
HRP20210200T1 (hr) * 2014-12-31 2021-04-02 Checkmate Pharmaceuticals, Inc. Kombinirana antitumorska imunoterapija
JP2018521979A (ja) * 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
JP7138094B2 (ja) * 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
WO2018115051A1 (en) * 2016-12-22 2018-06-28 F. Hoffmann-La Roche Ag Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
EP3740509A4 (en) * 2018-01-17 2022-06-22 Apexigen, Inc. Anti-pd-l1 antibodies and methods of use
CN119857138A (zh) 2018-09-13 2025-04-22 豪夫迈·罗氏有限公司 Csf-1r抗体制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016531150A (ja) 2013-09-12 2016-10-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体とヒトｐｄ−ｌ１に対する抗体の併用療法
WO2016011160A1 (en) 2014-07-15 2016-01-21 Genentech, Inc. Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎ Ｃａｎｃｅｒ Ｒｅｓ，２０１６．０８．０１，２２（１５），ｐ３８４９－３８５９

Also Published As

Publication number Publication date
JP2020502231A (ja) 2020-01-23
EP3558360A1 (en) 2019-10-30
US11498968B2 (en) 2022-11-15
CN110072553A (zh) 2019-07-30
US20190309078A1 (en) 2019-10-10
TW201828985A (zh) 2018-08-16
JP2022025088A (ja) 2022-02-09
CN110072553B (zh) 2023-09-15
WO2018115051A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP7742773B2 (ja) Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
JP7304287B2 (ja) 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
AU2017302668B2 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
JP6586454B2 (ja) ヒトｃｄ４０を活性化する抗体とヒトｐｄ−ｌ１に対する抗体との併用療法
AU2015292744C1 (en) Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
TWI617579B (zh) 抗人類ｃｓｆ－１ｒ抗體及抗人類ｐｄ－ｌ１抗體之組合療法
AU2016369537A1 (en) Antibody molecules to PD-1 and uses thereof
CN114272371A (zh) 包含抗pd-1抗体分子的联合疗法
JP6811733B2 (ja) リンパ腫又は白血病におけるリンパ球増加症を誘導することにおける使用のためのヒトｃｓｆ−１ｒに対する抗体
JP2020502231A5 (enExample)
JP7138094B2 (ja) マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP2023517044A (ja) 融合タンパク質およびその使用
EP3108897A1 (en) Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
HK40012429B (zh) 在抗pd-l1/pd1治疗失败之後抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
HK40012429A (en) Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
CA2955386C (en) Treatment of cancer using humanized anti-bcma chimeric antigen receptor
HK1252860B (zh) 用於在淋巴瘤或白血病中诱导淋巴细胞增多的针对人csf-1r的抗体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200903

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211015

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211025

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211026

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211126

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211207

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220830

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230418

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230425

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230626

R150 Certificate of patent or registration of utility model

Ref document number: 7304287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150